Contrasting of XOMA Corporation (XOMA) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

XOMA Corporation (NASDAQ:XOMA) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA Corporation 8.97M 11.84 11.23M -1.35 0.00
Tonix Pharmaceuticals Holding Corp. N/A 0.00 23.99M -28.85 0.00

Table 1 highlights XOMA Corporation and Tonix Pharmaceuticals Holding Corp.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
XOMA Corporation -125.20% -257.7% -25.6%
Tonix Pharmaceuticals Holding Corp. 0.00% -131.9% -116.8%

Volatility and Risk

XOMA Corporation is 164.00% more volatile than S&P 500 due to its 2.64 beta. Tonix Pharmaceuticals Holding Corp. has a 1.2 beta and it is 20.00% more volatile than S&P 500.


5.4 and 5.4 are the respective Current Ratio and a Quick Ratio of XOMA Corporation. Its rival Tonix Pharmaceuticals Holding Corp.’s Current and Quick Ratios are 6.8 and 6.8 respectively. Tonix Pharmaceuticals Holding Corp. has a better chance of clearing its pay short and long-term debts than XOMA Corporation.

Insider and Institutional Ownership

Institutional investors owned 49.1% of XOMA Corporation shares and 12.2% of Tonix Pharmaceuticals Holding Corp. shares. Insiders owned 7.5% of XOMA Corporation shares. On the other hand, insiders owned about 0.3% of Tonix Pharmaceuticals Holding Corp.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XOMA Corporation -1.86% 6.27% -14.09% -31.11% -55.68% -58.57%
Tonix Pharmaceuticals Holding Corp. -47.59% -58.09% -66.83% -93.64% -92.8% -92.12%

For the past year XOMA Corporation was less bearish than Tonix Pharmaceuticals Holding Corp.


On 6 of the 9 factors XOMA Corporation beats Tonix Pharmaceuticals Holding Corp.

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.